Indexing repetitive to single ventricular premature complexes

A new concept in acute drug testing

Kenneth M. Kessler, Agustin Castellanos, Robert J Myerburg

Research output: Contribution to journalArticle

Abstract

The clinical application of acute drug testing for the treatment of ventricular arrhythmias is limited by epidemiologic, statistical and therapeutic uncertainties. The suppression of ventricular premature complexes (VPCs) is confounded by statistical analyses that require high-grade suppression simply to confirm a true response1,2 and by the lack of clinical evidence of efficacy with respect to mortality.3 Repetitive forms of VPCs are generally considered more important than single VPCs,4 and improved clinical outcome has been associated with the high-grade suppression of repetitive forms in selected high-risk subgroups.5 However, the spontaneous variability of repetitive forms is frequently even more marked than single VPCs, rendering statistical analysis nearly impossible.6 Although these uncertainties have directed attention to the suppression of sustained and nonsustained ventricular tachycardia, both in drug development and therapies, there remains a clinical need to test acutely the efficacy of antiarrhythmic drugs against manifest ventricular arrhythmias. We report a new approach to this evaluation.

Original languageEnglish
Pages (from-to)648-650
Number of pages3
JournalThe American journal of cardiology
Volume67
Issue number7
DOIs
StatePublished - Mar 15 1991

Fingerprint

Ventricular Premature Complexes
Pharmaceutical Preparations
Uncertainty
Cardiac Arrhythmias
Anti-Arrhythmia Agents
Ventricular Tachycardia
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Indexing repetitive to single ventricular premature complexes : A new concept in acute drug testing. / Kessler, Kenneth M.; Castellanos, Agustin; Myerburg, Robert J.

In: The American journal of cardiology, Vol. 67, No. 7, 15.03.1991, p. 648-650.

Research output: Contribution to journalArticle

@article{989e2fe4a57e4faf9c71e1530c48af3b,
title = "Indexing repetitive to single ventricular premature complexes: A new concept in acute drug testing",
abstract = "The clinical application of acute drug testing for the treatment of ventricular arrhythmias is limited by epidemiologic, statistical and therapeutic uncertainties. The suppression of ventricular premature complexes (VPCs) is confounded by statistical analyses that require high-grade suppression simply to confirm a true response1,2 and by the lack of clinical evidence of efficacy with respect to mortality.3 Repetitive forms of VPCs are generally considered more important than single VPCs,4 and improved clinical outcome has been associated with the high-grade suppression of repetitive forms in selected high-risk subgroups.5 However, the spontaneous variability of repetitive forms is frequently even more marked than single VPCs, rendering statistical analysis nearly impossible.6 Although these uncertainties have directed attention to the suppression of sustained and nonsustained ventricular tachycardia, both in drug development and therapies, there remains a clinical need to test acutely the efficacy of antiarrhythmic drugs against manifest ventricular arrhythmias. We report a new approach to this evaluation.",
author = "Kessler, {Kenneth M.} and Agustin Castellanos and Myerburg, {Robert J}",
year = "1991",
month = "3",
day = "15",
doi = "10.1016/0002-9149(91)90909-5",
language = "English",
volume = "67",
pages = "648--650",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Indexing repetitive to single ventricular premature complexes

T2 - A new concept in acute drug testing

AU - Kessler, Kenneth M.

AU - Castellanos, Agustin

AU - Myerburg, Robert J

PY - 1991/3/15

Y1 - 1991/3/15

N2 - The clinical application of acute drug testing for the treatment of ventricular arrhythmias is limited by epidemiologic, statistical and therapeutic uncertainties. The suppression of ventricular premature complexes (VPCs) is confounded by statistical analyses that require high-grade suppression simply to confirm a true response1,2 and by the lack of clinical evidence of efficacy with respect to mortality.3 Repetitive forms of VPCs are generally considered more important than single VPCs,4 and improved clinical outcome has been associated with the high-grade suppression of repetitive forms in selected high-risk subgroups.5 However, the spontaneous variability of repetitive forms is frequently even more marked than single VPCs, rendering statistical analysis nearly impossible.6 Although these uncertainties have directed attention to the suppression of sustained and nonsustained ventricular tachycardia, both in drug development and therapies, there remains a clinical need to test acutely the efficacy of antiarrhythmic drugs against manifest ventricular arrhythmias. We report a new approach to this evaluation.

AB - The clinical application of acute drug testing for the treatment of ventricular arrhythmias is limited by epidemiologic, statistical and therapeutic uncertainties. The suppression of ventricular premature complexes (VPCs) is confounded by statistical analyses that require high-grade suppression simply to confirm a true response1,2 and by the lack of clinical evidence of efficacy with respect to mortality.3 Repetitive forms of VPCs are generally considered more important than single VPCs,4 and improved clinical outcome has been associated with the high-grade suppression of repetitive forms in selected high-risk subgroups.5 However, the spontaneous variability of repetitive forms is frequently even more marked than single VPCs, rendering statistical analysis nearly impossible.6 Although these uncertainties have directed attention to the suppression of sustained and nonsustained ventricular tachycardia, both in drug development and therapies, there remains a clinical need to test acutely the efficacy of antiarrhythmic drugs against manifest ventricular arrhythmias. We report a new approach to this evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0025971355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025971355&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(91)90909-5

DO - 10.1016/0002-9149(91)90909-5

M3 - Article

VL - 67

SP - 648

EP - 650

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -